Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. 1988

M C Hoogstraten, and R J van der Ploeg, and W vd Burg, and A Vreeling, and S van Marle, and J M Minderhoud
Department of Neurology, University Hospital, Groningen, The Netherlands.

Sixteen patients suffering from spasticity due to multiple sclerosis were treated with baclofen and tizanidine in a partially blind cross-over study. No significant difference in efficacy was found. The most striking difference was seen in the side-effects: baclofen frequently caused more or less severe muscle weakness and even falling during walking and standing. Treatment with tizanidine produced an apparent improvement of mobility in some patients suffering from moderate or marked paresis associated with a marked spasticity of their legs. Isometric muscle strength did not show any significant changes during either treatment. The different impact of baclofen and tizanidine on mobility and weight support seems to be related to their different site of action in spasticity.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D009128 Muscle Spasticity A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a "free interval") followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54) Clasp-Knife Spasticity,Spastic,Clasp Knife Spasticity,Spasticity, Clasp-Knife,Spasticity, Muscle
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D003000 Clonidine An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION. Catapres,Catapresan,Catapressan,Chlophazolin,Clofelin,Clofenil,Clonidine Dihydrochloride,Clonidine Hydrochloride,Clonidine Monohydrobromide,Clonidine Monohydrochloride,Clopheline,Dixarit,Gemiton,Hemiton,Isoglaucon,Klofelin,Klofenil,M-5041T,ST-155,Dihydrochloride, Clonidine,Hydrochloride, Clonidine,M 5041T,M5041T,Monohydrobromide, Clonidine,Monohydrochloride, Clonidine,ST 155,ST155
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M C Hoogstraten, and R J van der Ploeg, and W vd Burg, and A Vreeling, and S van Marle, and J M Minderhoud
February 1988, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
M C Hoogstraten, and R J van der Ploeg, and W vd Burg, and A Vreeling, and S van Marle, and J M Minderhoud
November 1989, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
M C Hoogstraten, and R J van der Ploeg, and W vd Burg, and A Vreeling, and S van Marle, and J M Minderhoud
August 1987, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
M C Hoogstraten, and R J van der Ploeg, and W vd Burg, and A Vreeling, and S van Marle, and J M Minderhoud
August 1975, American journal of physical medicine,
M C Hoogstraten, and R J van der Ploeg, and W vd Burg, and A Vreeling, and S van Marle, and J M Minderhoud
February 2006, Multiple sclerosis (Houndmills, Basingstoke, England),
M C Hoogstraten, and R J van der Ploeg, and W vd Burg, and A Vreeling, and S van Marle, and J M Minderhoud
August 1979, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
M C Hoogstraten, and R J van der Ploeg, and W vd Burg, and A Vreeling, and S van Marle, and J M Minderhoud
March 1987, Acta neurologica Scandinavica,
M C Hoogstraten, and R J van der Ploeg, and W vd Burg, and A Vreeling, and S van Marle, and J M Minderhoud
January 1981, Current medical research and opinion,
M C Hoogstraten, and R J van der Ploeg, and W vd Burg, and A Vreeling, and S van Marle, and J M Minderhoud
September 1975, Postgraduate medical journal,
M C Hoogstraten, and R J van der Ploeg, and W vd Burg, and A Vreeling, and S van Marle, and J M Minderhoud
January 2007, Acta neurochirurgica. Supplement,
Copied contents to your clipboard!